Microarrays 2013, 2(4), 318-339; doi:10.3390/microarrays2040318
Review

Lung Cancer Gene Signatures and Clinical Perspectives

1 Unit Cancer Genome Research, German Cancer Research Center and National Center for Tumor Diseases, Heidelberg 69120, Germany 2 Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research, Heidelberg 69120, Germany 
Received: 16 October 2013; in revised form: 19 November 2013 / Accepted: 6 December 2013 / Published: 13 December 2013
(This article belongs to the Special Issue Clinical Applications of Microarrays)
PDF Full-text Download PDF Full-Text [212 KB, uploaded 13 December 2013 18:03 CET]
Abstract: Microarrays have been used for more than two decades in preclinical research. The tumor transcriptional profiles were analyzed to select cancer-associated genes for in-deep functional characterization, to stratify tumor subgroups according to the histopathology or diverse clinical courses, and to assess biological and cellular functions behind these gene sets. In lung cancer—the main type of cancer causing mortality worldwide—biomarker research focuses on different objectives: the early diagnosis of curable tumor diseases, the stratification of patients with prognostic unfavorable operable tumors to assess the need for further therapy regimens, or the selection of patients for the most efficient therapies at early and late stages. In non-small cell lung cancer, gene and miRNA signatures are valuable to differentiate between the two main subtypes’ squamous and non-squamous tumors, a discrimination which has further implications for therapeutic schemes. Further subclassification within adenocarcinoma and squamous cell carcinoma has been done to correlate histopathological phenotype with disease outcome. Those tumor subgroups were assigned by diverse transcriptional patterns including potential biomarkers and therapy targets for future diagnostic and clinical applications. In lung cancer, none of these signatures have entered clinical routine for testing so far. In this review, the status quo of lung cancer gene signatures in preclinical and clinical research will be presented in the context of future clinical perspectives.
Keywords: lung cancer; NSCLC; biomarker; gene signature; testing

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Kuner, R. Lung Cancer Gene Signatures and Clinical Perspectives. Microarrays 2013, 2, 318-339.

AMA Style

Kuner R. Lung Cancer Gene Signatures and Clinical Perspectives. Microarrays. 2013; 2(4):318-339.

Chicago/Turabian Style

Kuner, Ruprecht. 2013. "Lung Cancer Gene Signatures and Clinical Perspectives." Microarrays 2, no. 4: 318-339.

Microarrays EISSN 2076-3905 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert